Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. CTEV
CTEV logo

CTEV Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
18.980
Open
17.910
VWAP
17.99
Vol
147.72K
Mkt Cap
291.33M
Low
17.400
Amount
2.66M
EV/EBITDA(TTM)
8.51
Total Shares
16.55M
EV
4.87B
EV/OCF(TTM)
41.46
P/S(TTM)
0.29
Claritev Corp, formerly MultiPlan Corporation, is a healthcare technology, data and insights company. The Company’s services include analytics-based services, data & decision science services, network-based services, payment and revenue integrity, end-to-end surprise billing service, and Claritev payments. The Company uses its analytics-based services to price surprise bills and leverages reimbursement data from millions of claims repriced through these services and accepted by providers to assist in negotiations and calculate offers for arbitration when necessary. It uses its payment integrity services on its network claims. The Company’s payment integrity offers advanced code editing, clinical negotiation, itemized bill review, coordination of benefits, subrogation, data mining, Medicare secondary payer validation, and end stage renal disease validation. It provides solutions for the commercial market, government healthcare plans, and property and casualty healthcare payors.
Show More

Events Timeline

(ET)
2026-02-23
16:20:00
Sees FY26 Adjusted EBITDA at $605M-$615M
select
2026-02-23
16:20:00
Claritev Reports Q4 Revenue of $246.6M
select
2026-01-21 (ET)
2026-01-21
08:20:00
Claritev Forms Strategic Relationship with Kinetiq Health
select
2025-11-12 (ET)
2025-11-12
23:23:06
Claritev Prices 1.5M Share Spot Secondary at $51.50
select
2025-11-12
16:14:58
Claritev to Offer 1.5 Million Shares of Class A Common Stock to Shareholders
select

News

Benzinga
2.0
03-05Benzinga
Middle East Conflict Heightens Market Uncertainty
  • Escalating Market Risks: The closure of the Strait of Hormuz disrupts approximately 20% of global oil and LNG flows, tightening insurance markets and prompting panic selling among investors, thereby exacerbating overall economic uncertainty.
  • Insider Buying Signals: Prior to the escalation of conflict, insiders at companies like CoStar Group, Hamilton Lane, Vornado Realty Trust, and Claritev Corporation made significant purchases, indicating their confidence in the long-term prospects of these firms, especially during turbulent market conditions.
  • Real Estate Market Recovery Expectations: Despite a brutal reset in the commercial real estate market, insider buying at CoStar Group suggests confidence in the normalization of future transaction activity, potentially driving a rebound in this sector.
  • Stability in Healthcare Technology: Insider purchases at Claritev Corporation before the conflict indicate that, despite heightened geopolitical risks, demand in the healthcare technology sector remains robust, expected to sustain stable cash flows and market positioning.
Newsfilter
1.0
03-03Newsfilter
Claritev Corporation to Host 2026 Investor Day at NYSE
  • Investor Day Event: Claritev Corporation will host its 2026 Investor Day on March 16, 2026, at the New York Stock Exchange, where the management team will discuss the company's long-term growth strategy, vertical markets, and financial outlook, likely drawing significant investor interest.
  • Live Webcast Details: The event will commence at 1:00 p.m. ET and will feature a live webcast, allowing investors to register and participate; a replay of the webcast will be available for one year post-event, ensuring accessibility for those unable to attend live.
  • Company Overview: Claritev focuses on enhancing healthcare affordability and transparency through technology and data, leveraging over 45 years of claims experience and AI solutions to provide actionable insights aimed at optimizing healthcare networks and benefits design.
  • Market Positioning and Goals: Claritev aims to deliver tailored solutions for all key stakeholders, including payers, employers, patients, and providers, with the objective of making healthcare more accessible and affordable, thereby strengthening its market position in the healthcare technology sector.
Globenewswire
7.0
02-25Globenewswire
Investigation into Claritev Corporation Investor Claims
  • Financial Performance Disclosure: Claritev Corporation reported an adjusted EBITDA margin of 61.4% for Q4 2025 and 62.4% for the full year, indicating stable profitability but failing to meet market expectations, which raises concerns about future performance.
  • Significant Stock Decline: Following the financial results announcement, Claritev's shares plummeted approximately 45%, reflecting investor anxiety regarding the company's growth prospects, particularly with a projected revenue growth of only 2% to 4% for 2026.
  • Legal Investigation Initiated: Johnson Fistel, PLLP is investigating whether Claritev's executives violated federal securities laws, potentially leading to claims for investor losses, highlighting concerns over corporate governance and transparency.
  • Investor Rights Protection: Johnson Fistel is recognized for its success in securities class actions, having recovered approximately $90.725 million for clients, demonstrating its capability and influence in safeguarding investor rights.
NASDAQ.COM
4.5
02-24NASDAQ.COM
Healthcare ETF Underperforms with Notable Declines
  • ETF Decline: The iShares U.S. Healthcare Providers ETF fell approximately 1.9% in Tuesday afternoon trading, indicating a lack of confidence in the healthcare sector that could influence investor asset allocation decisions.
  • Weak Individual Stocks: Within the ETF, Claritev's shares plummeted about 43.8%, while Addus Homecare dropped approximately 10.1%, raising concerns among investors regarding their future profitability and market positioning.
  • Market Reaction Analysis: The overall weakness in the healthcare sector may reflect market uncertainty regarding policy changes or economic outlook, prompting investors to closely monitor relevant policy developments to assess future investment risks.
  • Investor Sentiment Shift: The poor performance of the healthcare ETF may lead investors to reassess their investment strategies in the healthcare sector, potentially impacting capital inflows and market dynamics within the industry.
Benzinga
4.5
02-24Benzinga
U.S. Stocks Rise with Dow Jones Up Over 400 Points
  • Dow Jones Performance: On Tuesday, the Dow Jones index gained over 400 points, rising 0.84% to close at 49,213.73, indicating a strong market rebound and reflecting investor confidence in economic recovery.
  • NASDAQ and S&P 500: The NASDAQ surged 1.12% to 22,880.62, while the S&P 500 rose 0.79% to 6,891.92, suggesting robust performances in the technology and consumer sectors driving overall market gains.
  • Keurig Dr Pepper Earnings: Keurig Dr Pepper Inc. reported upbeat Q4 earnings with a 60 cents per share profit, surpassing the analyst consensus of 59 cents, and quarterly sales of $4.499 billion, exceeding the expected $4.361 billion, showcasing the company's competitive strength and growth potential.
  • Commodity Market Movements: Oil prices increased by 0.3% to $66.53, while gold fell by 0.9% to $5,179.60; silver rose 0.5% to $87.000, and copper climbed 1.9% to $5.8890, reflecting volatility in the commodity markets and shifts in investor risk appetite.
seekingalpha
9.5
02-24seekingalpha
Claritev Corporation Q4 2025 Earnings Highlights
  • Return to Profitability: Claritev Corporation achieved a 6.2% revenue growth in Q4 2025, totaling $246.6 million, demonstrating sustainable profitability in the healthcare technology sector, aligning with its long-term Vision 2030 strategy.
  • Innovative Product Launch: The introduction of the AI-driven Network Builder solution allows for the creation of provider networks in minutes, replacing lengthy manual processes, which is expected to significantly enhance customer satisfaction and drive future sales growth.
  • International Expansion Strategy: Claritev signed two additional clients in the Middle East, further expanding its international footprint and laying the groundwork for growth in 2026, indicating an accelerated strategic positioning in global markets.
  • Optimistic Financial Outlook: Management projects 2026 revenue guidance between $980 million and $1 billion, reflecting 2% to 4% growth, with adjusted EBITDA expectations of $605 million to $615 million, showcasing confidence in future growth prospects.
Wall Street analysts forecast CTEV stock price to rise
3 Analyst Rating
Wall Street analysts forecast CTEV stock price to rise
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
33.00
Averages
62.00
High
90.00
Current: 0.000
sliders
Low
33.00
Averages
62.00
High
90.00
Citi
Daniel Grosslight
Buy
downgrade
$63 -> $21
AI Analysis
2026-02-25
Reason
Citi
Daniel Grosslight
Price Target
$63 -> $21
AI Analysis
2026-02-25
downgrade
Buy
Reason
Citi analyst Daniel Grosslight lowered the firm's price target on Claritev to $21 from $63 and keeps a Buy rating on the shares.
Guggenheim
Buy
maintain
$43 -> $38
2026-02-24
Reason
Guggenheim
Price Target
$43 -> $38
2026-02-24
maintain
Buy
Reason
Guggenheim lowered the firm's price target on Claritev to $38 from $43 and keeps a Buy rating on the shares. Claritev reported "solid" Q4 results and while 2026 revenue and EBITDA guidance "optically fell slightly short of expectations," these can be explained away by conservatism on underlying topline drivers of the business and incremental investments via M&A flow-through and building out its international infrastructure, the analyst tells investors.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CTEV
Unlock Now

Valuation Metrics

The current forward P/E ratio for Claritev Corp (CTEV.N) is -2.26, compared to its 5-year average forward P/E of -3.39. For a more detailed relative valuation and DCF analysis to assess Claritev Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.39
Current PE
-2.26
Overvalued PE
-2.18
Undervalued PE
-4.61

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
8.89
Current EV/EBITDA
8.48
Overvalued EV/EBITDA
9.29
Undervalued EV/EBITDA
8.50

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.73
Current PS
0.57
Overvalued PS
1.01
Undervalued PS
0.44

Financials

AI Analysis
Annual
Quarterly

Whales Holding CTEV

A
Ares Management LLC
Holding
CTEV
+0.00%
3M Return
H
Hellman & Friedman LLC
Holding
CTEV
+0.00%
3M Return
G
GIC Special Investments Pte. Ltd.
Holding
CTEV
+0.00%
3M Return
T
Third Point LLC
Holding
CTEV
+0.00%
3M Return
T
The Public Investment Fund of The Kingdom of Saudi Arabia
Holding
CTEV
+0.00%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Claritev Corp (CTEV) stock price today?

The current price of CTEV is 17.6 USD — it has increased 4.2

What is Claritev Corp (CTEV)'s business?

Claritev Corp, formerly MultiPlan Corporation, is a healthcare technology, data and insights company. The Company’s services include analytics-based services, data & decision science services, network-based services, payment and revenue integrity, end-to-end surprise billing service, and Claritev payments. The Company uses its analytics-based services to price surprise bills and leverages reimbursement data from millions of claims repriced through these services and accepted by providers to assist in negotiations and calculate offers for arbitration when necessary. It uses its payment integrity services on its network claims. The Company’s payment integrity offers advanced code editing, clinical negotiation, itemized bill review, coordination of benefits, subrogation, data mining, Medicare secondary payer validation, and end stage renal disease validation. It provides solutions for the commercial market, government healthcare plans, and property and casualty healthcare payors.

What is the price predicton of CTEV Stock?

Wall Street analysts forecast CTEV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTEV is62.00 USD with a low forecast of 33.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Claritev Corp (CTEV)'s revenue for the last quarter?

Claritev Corp revenue for the last quarter amounts to 246.55M USD, increased 6.21

What is Claritev Corp (CTEV)'s earnings per share (EPS) for the last quarter?

Claritev Corp. EPS for the last quarter amounts to -4.87 USD, decreased -42.91

How many employees does Claritev Corp (CTEV). have?

Claritev Corp (CTEV) has 3000 emplpoyees as of March 17 2026.

What is Claritev Corp (CTEV) market cap?

Today CTEV has the market capitalization of 291.33M USD.